News

Luminoah, Rivanna Medical selected to prestigious med-tech accelerator

Two Charlottesville startups have been selected to MedTech Innovator, a well-known accelerator for medical technology startups.

Luminoah and Rivanna Medical are among 65 companies selected for the Los Angeles-based accelerator’s 2025 cohort. They will participate in a four-month program geared toward accelerating a path to U.S. market success.

Luminoah and Rivanna were both selected in the diagnostic and monitoring category. Luminoah, a former Lighthouse Labs demo day winner that closed a $6 million Series A round in 2023, has developed a mobile feeding tube for patients that collects data. Rivanna offers four products using ultrasound-based imaging technology that it says offer better precision and efficiency to health care professionals.

The MedTech Innovator program will include access to MedTech Innovator’s ecosystem of manufacturers, investors, providers, patients and more. The accelerator’s alumni have collectively brought more than 400 products to market and raised roughly $10 billion in follow-on funding, according to MedTech Innovator.

The 65 selected companies will compete for a share of $800,000 in nondilutive funding. The winners will be selected by audience vote at industry conferences.

MedTech Innovator said it received nearly 1,500 applicants to the program. It ultimately invited 213 companies to pitch at road tour events in Los Angeles, Dublin and College Park, Maryland, and then whittled that field down to 65.

The cohort represents 13 countries and 17 U.S. states.

Read more here.

Recent News

10/22/2025

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan